Pasar al contenido principal

(RE)MIELINIZACION EN ESCLEROSIS MULTIPLE Y LEUCODISTROFIAS DESMIELINIZANTES RARAS: DESARROLLO DE MODELOS DE ENFERMEDAD IN VITRO E IN VIVO PARA CONSEGUIR PRODUCIR MIELINA

PID2022-143110OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Efficacy of a benzothiazole-based LRRK2 inhibitor in oligodendrocyte precursor cells and in a murine model of multiple sclerosis

  • Benítez-Fernández, Rocío
  • Josa-Prado, Fernando
  • Sánchez, Estefanía
  • Lao, Yolanda
  • García-Rubia, Alfonso
  • Cumella, José
  • Martínez, Ana
  • Palomo, Valle
  • Castro Soubriet, Fernando de
Multiple sclerosis (MS) is a chronic neurological disease that currently lacks effective curative treatments. There is a need to find effective therapies, especially to reverse the progressive demyelination and neuronal damage. Oligodendrocytes form the myelin sheath around axons in the central nervous system (CNS) and oligodendrocyte precursor cells (OPCs) undergo mechanisms that enable spontaneously the partial repair of damaged lesions. The aim of this study was to discover small molecules with potential effects in demyelinating diseases, including (re)myelinating properties., Comunidad de Madrid, Grant/Award Number: PEJ-2019-TL/BMD-1426; Consejo Superior de Investigaciones Científicas, Grant/Award Number: 2023AEP096; Fundación Ramón Areces, Grant/Award Number: CIVP19A5917; Ministerio de Ciencia e Innovación, Grant/ Award Number: PID2019-109858RB-I00, PID2022-143110OB-I00 and RYC2019- 027489-I, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Activation of Shh/Smo is sufficient to maintain oligodendrocyte precursor cells in an undifferentiated state and is not necessary for myelin formation and (re)myelination.

  • Nocera, Sonia
  • Marchena, Miguel A.
  • Fernández-Gómez, Beatriz
  • Gómez-Martín, Paula
  • Sánchez-Jiménez, Estefanía
  • Macías-Castellano, A.
  • Lao, Yolanda
  • Cordano, C.
  • Gómez-Torres, Óscar
  • Luján, Rafael
  • Castro Soubriet, Fernando de
Myelination is the terminal step in a complex and precisely timed program that orchestrates the proliferation, migration and differentiation of oligodendroglial cells. It is thought that Sonic Hedgehog (Shh) acting on Smoothened (Smo) participates in regulating this process, but that these effects are highly context dependent. Here, we investigate oligodendroglial development and remyelination from three specific transgenic lines: NG2-CreERT2 (control), Smofl/fl/NG2-CreERT2 (loss of function), and SmoM2/NG2-CreERT2 (gain of function), as well as pharmacological manipulation that enhance or inhibit the Smo pathway (Smoothened Agonist (SAG) or cyclopamine treatment, respectively). To explore the effects of Shh/Smo on differentiation and myelination in vivo, we developed a highly quantifiable model by transplanting oligodendrocyte precursor cells (OPCs) in the retina. We find that myelination is greatly enhanced upon cyclopamine treatment and hypothesize that Shh/Smo could promote OPC proliferation to subsequently inhibit differentiation. Consistent with this hypothesis, we find that the genetic activation of Smo significantly increased numbers of OPCs and decreased oligodendrocyte differentiation when we examined the corpus callosum during development and after cuprizone demyelination and remyelination. However, upon loss of function with the conditional ablation of Smo, myelination in the same scenarios are unchanged. Taken together, our present findings suggest that the Shh pathway is sufficient to maintain OPCs in an undifferentiated state, but is not necessary for myelination and remyelination., This research was supported by the Spanish Ministerio de Ciencia e Investigación-MCIN/Spanish Research Agency-AEI (grants SAF2012-400232, SAF2016-77575-R, RD12-0032/0012, RD16-0015/0019,PID2019-109858RB-I00, EIN2020-112366, and PID2022-143110OB-I00-MCIN/AEI/10.13039/501100011033/-), CSIC/Spanish ResearchCouncil (grants BDC-20213231 and 2023AEP096), and FundaciónRamón Areces (Spain; grant CIVP19A5917), and a grant from Proyectosde Investigación Relacionados con las Enfermedades Raras Infantiles from Fundación Inocente Inocente (Spain), all to F. dC. SN had a predoctoral contract of the Universidad de Castilla-La Mancha, and then was hired under grant IND2018/BMD-9751 (Comunidad de Madrid, Spain) to F.dC. BF-G was predoctoral researcher contracted under IND2018/BMD-9751 (Programa de Doctorados Industriales de la Comunidad de Madrid, Spain), to F.dC. YL was hired under grants from Spanish Ministerio de Ciencia e Investigación-MCIN/Spanish Research Agency-AEIRD16/0015/0019 and PID2019-109858RB-I00. PG-M is currently hired under PID2022-143110OB-I00. We are deeply in debt with Mrs.Laudelina Garmendia for her unvaluable help in the Animal Facilities of the Instituto Cajal: she did almost miracles during pandemics to keep alive mice colonies in numbers enough to allow fast restarting of experiments once de confined. Finally, we would like to thank Dr. Javier Mazarío (Hospital Nacional de Parapléjicos, Toledo, Spain) for his invaluable help in the confocal microscopy and quantification advice
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Herpes Simplex Virus type 1 inhibits autophagy in glial cells but requires ATG5 for the success of viral replication.

  • Ripa, Inés
  • Andreu, Sabina
  • Fernández-Gómez, Beatriz
  • Josa-Prado, Fernando
  • Castro Soubriet, Fernando de
  • Arribas, María
  • Bello-Morales, Raquel
  • López-Guerrero, José Antonio
Herpes Simplex Virus type 1 (HSV-1) 1 is a neurotropic virus that has been associated with neurodegenerative disorders. The dysregulation of autophagy by HSV-1 has been proposed as a potential cause of neurodegeneration. While studies have extensively tackled the interaction between autophagy and HSV-1 in neurons, research in glial cells is currently limited. Our studies demonstrate that HSV-1 inhibits, but not completely blocks, the formation of autophagosomes in human oligodendroglioma- and astrocytoma- derived cell lines. These findings have been confirmed in murine oligodendrocyte precursor cells (OPCs). Finally, this study investigates the impact of autophagy on HSV-1 infection in glial cells. While the lack of basal autophagy in LC3B knockout glial cells does not have a significant effect on viral infection, cells without the autophagy-related protein ATG5 exhibit reduced viral production. The absence of ATG5 leads to a decrease in the transcription and replication of viral genes, as well as a delay in the initial stages of the formation of HSV-1 replication compartments. These findings indicate that while autophagy may not play a significant role in antiviral defense in glial cells, HSV-1 may be inhibiting autophagy to exploit non-canonical functions of certain components of the autophagic machinery, such as ATG5, to benefit its lifecycle., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by Ministerio de Ciencia e Innovación, Spain (grants number PID2019-110570GB-I00 to JL-G and PID2019-109858RB-I00 and PID2022-143110OB-I00 (funded by MCIN/AEI/ 10.13039/501100011033) to FC). BF-G was predoctoral researcher contracted under IND2018/BMD-9751 (Programa de Doctorados Industriales de la Comunidad de Madrid, Spain), to FC. FJ-P was hired under grant CIVP19A5917 from Fundación Ramón Areces (Spain) to FC.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ApTOLL: A new therapeutic aptamer for cytoprotection and (re)myelination after multiple sclerosis

  • Fernández-Gómez, Beatriz
  • Marchena, Miguel A
  • Piñeiro, David
  • Gómez-Martín, Paula
  • Sánchez, Estefanía
  • Laó, Yolanda
  • Valencia, Gloria
  • Nocera, Sonia
  • Benítez-Fernández, Rocío
  • Castaño-León, Ana M
  • Lagares, Alfonso
  • Hernández-Jiménez, Macarena
  • Castro Soubriet, Fernando de
ApTOLL is an aptamer selected to antagonize toll-like receptor 4 (TLR4), a relevant actor for innate immunity involved in inflammatory responses in multiple sclerosis (MS) and other diseases. The currently available therapeutic arsenal to treat MS is composed of immunomodulators but, to date, there are no (re)myelinating drugs available in clinics. In our present study, we studied the effect of ApTOLL on different animal models of MS., This work was supported by the following grants and contractsto FdC: IND2018/BMD-9751 (Programa de Doctorados Industriales,Comunidad de Madrid, Spain); SAF2016-77575-R, PID2019-109858RB-I00, PID2022-143110OB-I00, EIN2020-112366 and RD16/0015/0019 (grant funded by the Spanish Ministerio de Ciencia Investigación e Innovación—MCIN/AEI/10.13039/501100011033and by ‘ERDF a way of making Europe’ by the European Union), 2019AEP033 (from Consejo Superior de Investigaciones Científicas—CSIC, Spain), and a contract for technological support (20184174) from Apta Targets SL (Spain). BF-G is currently hired by Apta Targets SL; PG-M was contracted as Ayudante de Investigación (PEJ-2020-AI/BMD-18541), associated with the Fondo de Garantía Juvenil (call 2020), financed by Comunidad de Madrid (Spain) and now hired under Grant 2019AEP033; SN was hired under IND2018/BMD-9751 (to FdC); and YL has been contracted under RD16/0015/0019 andPID2019-109858RB-I00. We thank David Segarra and Mª Eugenia Zarabozo (AptaTargets SL) for their constant technological support,Laude Garmendia for her indispensable constant help at the animal facility (Instituto Cajal—CSIC), including the extra effort during COVID-19 pandemics, and Dr. Carolina Melero-Jerez (a former mem-ber of the FdC research group, currently working at Jazz Pharma,Spain) for the initial training of BF-G on the EAE animal model and dif-ferent techniques at the laboratory., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Miguel A. Merchán and the Cajalian influence: Pioneering Auditory Neuroscience in Spain.

  • Saldaña, E.
  • Castro Soubriet, Fernando de
  • López, Dolores E.
  • Malmierca, M.S.
This article traces the history of auditory neuroscience in Spain. It begins with the pioneering contributions of Santiago Ramón y Cajal, who meticulously described the organization of every region of the auditory system, from the cochlea to the cerebral cortex. His legacy continued with his disciples, Rafael Lorente de Nó, who conducted a detailed study of the cochlear nuclei, and Fernando de Castro, who later passed the baton to Jaime A. Merchán. Jaime Merchán revitalized Spanish auditory neuroscience and mentored his brother Miguel, whose contributions receive special focus. Starting in the early 1980s, Miguel A. Merchán's pioneering research has profoundly expanded our understanding of the structure and connectivity in the central auditory system. His collaborations, both within Spain and internationally, have played a pivotal role in shaping the field. As his career progressed, his research evolved to investigate the plasticity of the auditory system, and his recent work continues to explore innovative approaches to protect and restore hearing, with significant clinical implications. Beyond his scientific accomplishments, Miguel Merchán's influence as a mentor and administrator further highlights his enduring legacy. His contributions have not only advanced the field but have also nurtured the development of future generations of Spanish scientists, encouraging collaboration and innovation in the scientific community. His work continues to inspire emerging researchers, while his ongoing investigations into auditory system plasticity and protection hold promise for vital breakthroughs in the understanding and treatment of hearing loss and related disorders., During preparation of this manuscript, our laboratories were supported by MCIN/AEI/10.13039/501100011033 (projects PID2019- 104570RB-I00 and PID2023-148541OB-I00 to M.S.M. and E.S., and project PID2022-143110OB-I00 to F.d.C), by Consejería de Educación, Junta de Castilla y León grants SA218P23 (to M.S.M. and E.S.) and SA072G24 (to D.E.L.), and by Foundation Ramón Areces grant CIVP20A6616 (to M.S.M.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Miguel A. Merchán and the Cajalian influence: Pioneering Auditory Neuroscience in Spain.

  • Saldaña, E.
  • Castro Soubriet, Fernando de
  • López, Dolores E.
  • Malmierca, M.S.
This article traces the history of auditory neuroscience in Spain. It begins with the pioneering contributions of Santiago Ramón y Cajal, who meticulously described the organization of every region of the auditory system, from the cochlea to the cerebral cortex. His legacy continued with his disciples, Rafael Lorente de Nó, who conducted a detailed study of the cochlear nuclei, and Fernando de Castro, who later passed the baton to Jaime A. Merchán. Jaime Merchán revitalized Spanish auditory neuroscience and mentored his brother Miguel, whose contributions receive special focus. Starting in the early 1980s, Miguel A. Merchán's pioneering research has profoundly expanded our understanding of the structure and connectivity in the central auditory system. His collaborations, both within Spain and internationally, have played a pivotal role in shaping the field. As his career progressed, his research evolved to investigate the plasticity of the auditory system, and his recent work continues to explore innovative approaches to protect and restore hearing, with significant clinical implications. Beyond his scientific accomplishments, Miguel Merchán's influence as a mentor and administrator further highlights his enduring legacy. His contributions have not only advanced the field but have also nurtured the development of future generations of Spanish scientists, encouraging collaboration and innovation in the scientific community. His work continues to inspire emerging researchers, while his ongoing investigations into auditory system plasticity and protection hold promise for vital breakthroughs in the understanding and treatment of hearing loss and related disorders., During preparation of this manuscript, our laboratories were supported by MCIN/AEI/10.13039/501100011033 (projects PID2019- 104570RB-I00 and PID2023-148541OB-I00 to M.S.M. and E.S., and project PID2022-143110OB-I00 to F.d.C), by Consejería de Educación, Junta de Castilla y León grants SA218P23 (to M.S.M. and E.S.) and SA072G24 (to D.E.L.), and by Foundation Ramón Areces grant CIVP20A6616 (to M.S.M.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Isolation of Oligodendrocyte Precursor Cells with Immunomagnetic Beads for Their Better Viability In Vitro and In Vivo.

  • Gómez-Martín, Paula
  • Macías-Castellano, Alba
  • Fernández-Gómez, Beatriz
  • Sánchez-Jiménez, Estefanía
  • Marchena, Miguel
  • Castro Soubriet, Fernando de
Oligodendrocytes (OLs) are glial cells that myelinate axons in the central nervous system (CNS). These cells are generated from oligodendrocyte precursor cells (OPCs) during CNS development, and the population of OPCs that remain in the adult is responsible for spontaneous remyelination in demyelinating diseases such as multiple sclerosis (MS). Thus, OPCs represent an interesting source for regenerative therapies. Here, we describe an updated protocol for isolation of OPCs based on the magnetic cell separation (MACS) technology and oligodendroglial lineage-specific markers. After the extraction of nerve tissue, mechanical and enzymatic dissociation is performed. The cells are then immunomagnetically labeled and separated through columns composed of a matrix of ferromagnetic spheres coupled to the magnetic field of the MACS separator. This method has several advantages: it is significantly more efficient and faster if compared to other conventional methods, such as flow cytometry or shaking. In addition, the OPCs isolated in this way are significantly more viable, which facilitates their use of these cells in different experimental approaches, both in vitro and in vivo., FdC and his research group are currently supported by the following Spanish institutions: Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (grant PID2022-143110OB-100— funded by MCIN/AEI/10.13039/501100011033 FEDER/EU-), Fundación Ramón Areces (grant CIVP19A5917), Fundación Merck Salud (Ayudas Merck de Investigación 2023), Fundación GAEM (contract # 050601240006), Asociación Europea contra la leucodistrofia-ELA España and Fundación Hesperia (contract # 050601240019) all to FdC. The research group is also part of research networks #RED2022-134081-T and # RED2022-134425-T, both financed by the Spanish Agencia Estatal de Investigación. PG-M was contracted as Ayudante de Investigación (PEJ-2020-AI/BMD-18541, associated with the Fondo de Garantía Juvenil, Comunidad de Madrid, Spain, to FdC) and now hired under grant PID2022-143110OB-100. BF-G was hired under IND2018/BMD-9751 (Programa de Doctorados Industriales, Comunidad de Madrid) to FdC, and she is currently hired by AptaTargets, SL. AM-C is currently hired under Fundación Merck Salud (Ayudas Merck de Investigación 2023). We are deeply indebted to Dr. Ana Bribián (Sanofi, Spain) and Dr. Carolina Melero-Jerez (JazzPharma, Spain), previous members of our research group, for their fundamental contributions that paved the path to reach the present protocol.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Miguel A. Merchán and the Cajalian influence: Pioneering auditory neuroscience in Spain

  • Saldaña, Enrique
  • de Castro, Fernando
  • López, Dolores E
  • Malmierca, Manuel S
This article traces the history of auditory neuroscience in Spain. It begins with the pioneering contributions of Santiago Ramón y Cajal, who meticulously described the organization of every region of the auditory system, from the cochlea to the cerebral cortex. His legacy continued with his disciples, Rafael Lorente de Nó, who conducted a detailed study of the cochlear nuclei, and Fernando de Castro, who later passed the baton to Jaime A. Merchán. Jaime Merchán revitalized Spanish auditory neuroscience and mentored his brother Miguel, whose contributions receive special focus. Starting in the early 1980s, Miguel A. Merchán's pioneering research has profoundly expanded our understanding of the structure and connectivity in the central auditory system. His collaborations, both within Spain and internationally, have played a pivotal role in shaping the field. As his career progressed, his research evolved to investigate the plasticity of the auditory system, and his recent work continues to explore innovative approaches to protect and restore hearing, with significant clinical implications. Beyond his scientific accomplishments, Miguel Merchán's influence as a mentor and administrator further highlights his enduring legacy. His contributions have not only advanced the field but have also nurtured the development of future generations of Spanish scientists, encouraging collaboration and innovation in the scientific community. His work continues to inspire emerging researchers, while his ongoing investigations into auditory system plasticity and protection hold promise for vital breakthroughs in the understanding and treatment of hearing loss and related disorders., During preparation of this manuscript, our laboratories were supported by MCIN/AEI/10.13039/501100011033 (projects PID2019-104570RB-I00 and PID2023-148541OB-I00 to M.S.M. and E.S., and project PID2022-143110OB-I00 to F.d.C), by Consejería de Educación, Junta de Castilla y León grants SA218P23 (to M.S.M. and E.S.) and SA072G24 (to D.E.L.), and by Foundation Ramón Areces grant CIVP20A6616 (to M.S.M.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cell-based regenerative interventions in Parkinson's disease: Overcoming pharmacological limitations

  • Padilla, Ana Lizeth
  • Lanciego, José Luis
  • Vila, Miquel
  • Castro Soubriet, Fernando de
  • Pozo, David
  • Rodríguez de Fonseca, Fernando
  • Serrano, Antonia
  • Sáez-Valero, Javier
  • Núñez, Lucía
  • Villalobos, Carlos
  • Tapias, Víctor
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic (DA) neurons and the pathological aggregation of α-synuclein. While current pharmacological therapies provide symptomatic relief, they do not halt or reverse disease progression. Cell-based regenerative strategies have emerged as promising approaches to restore DA function and target the complex, multifactorial pathophysiology of PD. This review critically examines current approaches, including transplantation of fetal ventral mesencephalic tissue, pluripotent stem cell-derived midbrain DA progenitors, and in vivo reprogramming of endogenous cells. In addition, supportive cell types, such as mesenchymal stromal cells and carotid body glomus cells, provide neuroprotective and immunomodulatory effects via paracrine signaling. We summarize preclinical and clinical evidence on graft survival, integration, and functional recovery, and discuss key determinants of therapeutic efficacy, including mitochondrial function and bioenergetic integrity, immune compatibility, and biomaterial scaffolding. Despite significant progress, major challenges remain regarding long-term efficacy, graft standardization, and host-graft interactions. Ongoing translational advances are poised to drive the development of disease-modifying cell therapies capable of delivering durable clinical benefits and improving long-term outcomes in PD., This work was supported by the Aligning Science Across Parkinson's (#ASAP-020505, USA) through the Michael J. Fox Foundation for Parkinson's Research (MJFF), Ministerio de Ciencia, Innovación y Universidades y Agencia Estatal de Investigación (MICIN/AEI, #PID2020-120308RB, Spain), CiberNed Intramural Collaborative Projects (#PI2020/09, Spain) and Fundación Mutua Madrileña de Investigación Médica (#FMM2020, Spain) to José L. Lanciego; Aligning Science Across Parkinson's (#ASAP-020505, USA) through the MJFF (USA), MICIN/AEI (#PID2020-116339RB-I00, Spain) to Miquel Vila; MICIN/AEI (#PID2022-143110OB-100, Spain), Fundación Ramón Areces (#CIVP19A5917, Spain), Fundación Merck Salud (2023, Spain) and Fundación Grupo de Afectados por Esclerosis Multiple (GAEM, #050601240006, Spain) in collaboration with research networks #RED2022-134081-T and #RED2022-134425-T to Fernando de Castro; MICIN/AEI (#PI22/00427 and #PI20/01399, Spain) and European Regional Development Funds-European Union (ERDF-EU) to Fernando Rodríguez de Fonseca and Antonia Serrano; MICIN/AEI (#RTI2018-098432-BI00), Junta de Andalucía (#PI-232-2022 and #CTS-677), Fundació Catalana d’ELA Miquel Valls (2022, Spain), Fundación Juntos contra la ELA (2023, Spain) to David Pozo; Fondo de Investigaciones Sanitarias (#PI22/01329, Spain), Fondo Europeo de Desarrollo Regional (FEDER), and Dirección General de Ciencia e Investigación de la Generalitat Valenciana (CIAICO/2024/313, Spain) to Javier Sáez-Valero; Excellence Program from Junta de Castilla y León (#CCVC8485, Spain) and MICIN/AEI (#PID2021-125909OB-100, Spain) to Carlos Villalobos and Lucía Núñez, and Junta de Castilla y León (#VA294P18, Spain) to Lucía Núñez; María Zambrano's Excellence Program from the MICIN/AEI (#CONVREC-2021-278, Spain), University of Valladolid and the Internationalization program of Junta de Castilla y León (#CL-EI-2021-09, Spain) to Victor Tapias., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New integrated three-interface conceptual model for clearance and immune surveillance in the human CNS

  • García-Cosamalón, José
  • Marchena, Miguel A.
  • Villar-Suárez, Vega
  • Ley, Luis
  • Castro Soubriet, Fernando de
The central nervous system (CNS) lacks a classical lymphatic system and instead relies on cerebrospinal fluid (CSF) circulation for metabolic waste removal and for defense/immune surveillance. Recent research has consolidated the concept of an integrated glymphatic-lymphatic continuum (because of the relevant contribution of glial cells), where CSF acts as a central transport medium linking parenchymal exchange with meningeal lymphatic outflow. Within this framework, the glymphatic system supports CSF-interstitial fluid exchange, particularly during sleep, when vascular pulsatility enhances solute clearance. Translating insights from rodent systems to the human brain, however, requires explicit consideration of the subarachnoid space and CSF hydrodynamics as an intermediate interface that distributes CSF and modulates the balance between parenchymal influx and efflux toward dural lymphatics. We here propose a three-phase conceptual model comprising: (1) a microscale segment that includes perivascular spaces, the neuropil/interstitial compartment, glial elements, and aquaporin-mediated water transport; (2) a mesoscale segment centered on the arachnoid barrier and the subarachnoid CSF compartment, functioning as a distribution and exchange interface; and (3) a macroscale segment encompassing arachnoid granulations and dural meningeal lymphatic vessels as the principal egress pathways. To further support this with a clinical perspective, we review evolutionary adaptations that have resulted in more efficient fluid exchange between CSF reservoirs and the extracellular space of the human brain. This three-interface framework may improve diagnostic and therapeutic precision by recognizing that the distinct disorders, such as neurodegenerative proteinopathies, cerebral edema, hydrocephalus, or meningoencephalitis, preferentially disrupt specific interfaces across scales., The author(s) declared that financial support was received for this work and/or its publication. Our research groups were supported by Fundación Leonesa para las Neurociencias (JG-C and VV-S), by the Spanish Ministerio de Ciencia, Innovación y Universidades MCIN/AEI/10.13039/501100011033/ and by “ERDF A way of making Europe”, by the European Union (grants PID2022-143110OB-I00 and RED2024-153909-E to FC), by Asociación Europea contra la Leucodistrofia-ELA España and Fundación Hesperia (contracts #050601240019 and #050601250032 “LeukoReMy” to FC), and by Universidad Camilo José Cela-UCJC (grant from the XI Convocatoria de Ayudas a la Investigación to MM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders

  • Alvaro-Espinosa, Laura
  • Marquez-Galera, Angel
  • Priego, Neibla
  • García-Calvo, Virginia
  • Perea-García, Maria
  • Hernandez-Oliver, Carolina
  • Retana, Diana
  • Sanchez, Oliva
  • Pablos-Aragoneses, Ana de
  • García-Gómez, Pedro
  • Graña-Castro, Osvaldo
  • Lapuente-Santana, Óscar
  • Serrano-Ron, Laura
  • Al-Shahrour, Fatima
  • Cayuela López, Ana
  • Peset, Isabel
  • Megías, Diego
  • Ola, Mihaela
  • Varešlija, Damir
  • Young, Leonie S.
  • Martí-Mateos, Yolanda
  • Enríquez, Jose A.
  • Hernández-Encinas, Elena
  • Blanco-Aparicio, Carmen
  • Soengas, María S.
  • Bernhagen, Juergen
  • Antón-Fernández, Alejandro
  • Ávila, Jesús
  • Marchena, Miguel A.
  • Torres, Maximiliano
  • Castro Soubriet, Fernando de
  • Márquez-Ropero, Mar
  • Sierra, Amanda
  • López-Atalaya, José P.
  • Valiente, Manuel
  • RENACER Group
The upregulation of CD74, a chaperone involved in MHC-II antigen processing, has been mostly interpreted as indicative of antigen presentation in multiple brain disorders. However, CD74 expression has also been described in cancer cells across multiple tumor types and in the tumor microenvironment, notably in glioma. In this study, we found that the presence of CD74+ microglia/macrophages, which was induced by increased levels of interferon γ in brains affected by metastases, did not relate to its canonical pathway. Instead, the alternative function of CD74 as a cytokine receptor was pivotal. Proliferating cancer cells produced high levels of the ligand migration inhibitory factor (MIF) that bound the CD74 receptor and induced its translocation to the nucleus where it activated an NF-κB-dependent program that promoted metastatic progression. In patients, a CD74 signature was associated with more aggressive progression of brain metastatic disease, although it had no clinical correlation with the matched primary tumor. Interestingly, a pan-disease noncanonical and clinically relevant signature derived from the CD74+ myeloid population was identified that occurred in additional brain disorders, including Alzheimer's disease and multiple sclerosis. The brain-penetrant drug ibudilast, which prevents the binding of MIF to CD74, decreased brain metastasis in experimental models in vivo and in patient-derived organotypic cultures ex vivo in a primary tumor-agnostic manner. These findings suggest that MIF/CD74-induced reprogramming of myeloid cells in brain disorders is a vulnerability that could be exploited therapeutically against brain metastases and possibly other brain disorders., We thank all members of the Brain Metastasis Group for critical discussion of the manuscript; the CNIO Core Facilities for their excellent assistance; and Estefanía Sánchez-Jiménez (F. de Castro laboratory at Instituto Cajal-CSIC) and the staff at the Animal Facilities of the Instituto Cajal-CSIC for their extraordinary help with animals of the cuprizone demyelinating murine model of multiple sclerosis. Special thanks to patients and their families who donated valuable materials to RENACER and all site personnel, investigators, funders, and industry partners who supported the generation of the data within this study. Postmortem cortical brain tissue blocks from patients with multiple sclerosis and controls, as well as the associated clinical and neuropathologic data, were supplied by the Multiple Sclerosis & Parkinson’s Tissue Bank at Imperial College (London, United Kingdom), funded by the Multiple Sclerosis Society of Great Britain and Northern Ireland, registered charity 207495. We thank J. Massagué (MSKCC) for some of the BrM cell lines. This study was funded by La Marató (201906-30-31-32; M. Valiente), MICIU (SAF2017-89643-R, SAF2014-57243-R, and SAF2015-62547-ERC to M. Valiente; PID2022-143110OB-I00 and RED2024-153909-E to F. de Castro), H2020-FETOPEN (828972; M. Valiente), Bristol Myers Squibb MRA Young Investigator Award (498103; M. Valiente), Cancer Research Institute (Clinic and Laboratory Integration Program CRI Award 2018; 54545; M. Valiente), LAB AECC 2019 (LABAE19002VALI; M. Valiente), AECC Coordinados (PRYCO234528VALI; M. Valiente), ERC CoG (864759; M. Valiente), and ERANET-TRANSCAN-3 (TRANSCAN2021-203; M. Valiente) with funds from Instituto de Salud Carlos III/NextGenerationEU/PRTR (AC20/00114) and FC AECC (TRNSC213878VALI), CaixaResearch Health (HR23-00051; M. Valiente), MINECO-Ramón y Cajal (RYC-2013-13365; M. Valiente), MICIU/AEI/10.13039/501100011033 and ERDF (RTI2018-102260-B-I00; J.P. Lopez-Atalaya), Generalitat Valenciana (PROMETEO/2020/007; J.P. Lopez-Atalaya), Ramón Areces Foundation (CIVP20S10662 to E. Ortega-Paino/M.-J. Artiga; CIVP19S8163 to M. Valiente; and CIVP19A5917 to F. de Castro), Spanish Ministry of Science and Innovation Competitiveness MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” (RTI2018-099267-B-I00 and PID2022-136698OB-I00; A. Sierra), Basque Government grants (IT1473-22; A. Sierra), Alzheimer Association award (AARG-NTF-24-1304352; A. Sierra), Breast Cancer Ireland (18239A01; L.S. Young), Research Ireland (19/FFP/6443; L.S. Young, 20/FFP-P/8597; D. Varešlija, and 23/SPP/11783; L.S. Young, D. Varešlija), Breast Cancer Now (2021 July PCC1460; L.S. Young, D. Varešlija, 2019 Aug SF1310 with the generous support of Walk the Walk; D. Varešlija), MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/Plan de Recuperación Transformación y Resiliencia, PRTR (RTI2018-099357-B-I00, PID2021-1279880B, and TED2021-131611B-I00; J.A. Enríquez), CIBERFES (CB16/10/00282; J.A. Enríquez), Foundation Leducq (17CVD04; J.A. Enríquez), MCIN/AEI/10 PID2023-147213OB-I00 (M.S. Soengas), ERC-Advanced Grant 884699 (M.S. Soengas), La Caixa International PhD Program Fellowship-Marie Sklodowska-Curie (LCF/BQ/DI17/11620028; P. García-Gómez and LCF/BQ/DI19/11730044; A. de Pablos-Aragoneses), AECC postdoctoral fellowship (POSTD19016PRIE; N. Priego), MINECO-Severo Ochoa PhD Fellowship (BES-2017-081995; L. Alvaro-Espinosa), FPI-Severo Ochoa Fellowship PRE2018-083478 awarded by MICIU/AEI/10.13039/501100011033, and European Social Funds (FSE invierte en tu futuro; Y. Martí-Mateos). M. Valiente is an EMBO YIP member (4053). The CNIC is supported by the Instituto de Salud Carlos III, the Ministerio de Ciencia, Innovación y Universidades, and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033). The Instituto de Neurociencias is a “Centre of Excellence Severo Ochoa” (CEX2021-001165-S funded by MCIU/AEI/10.13039/501100011033). CNIO is supported by the ISCIII, the Ministerio de Ciencia e Innovación, and is a Severo Ochoa Center of Excellence (SEV-2015-0510)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2020-001041-S), With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Neurovascular Niche: A Gathering Venue for Neuroinflammation and Remyelination in Multiple Sclerosis

  • Kazanis, Ilias
  • Silva, Maria Elena
  • Fuente, Alerie G. de la
  • Castro Soubriet, Fernando de
  • Rivera, Francisco J.
In the central nervous system (CNS), the tissue microenvironment is continuously monitored and regulated to secure the unobstructed function of neurons and of their networks. This is a key function of the neurovascular niche (NVN), which is the interface between the cells of the nervous tissue and the cells and the content of blood vessels. It is enabled by the Blood-Brain Barrier, a structure formed by endothelial and perivascular cells, extracellular matrix, and astrocytes, and is manifested by the limited surveillance of the CNS from blood-derived cells. Multiple sclerosis (MS) is a devastating degenerative disorder, in which the myelin sheaths that enwrap neuronal axons are destroyed, leading, over time, to neurological symptoms. MS has a strong immunological component which is targeted in most of the current disease-modifying treatments. Nevertheless, regenerative interventions aiming at enhancing and restoring the endogenous remyelination potential of the CNS, driven by the abundant Oligodendrocyte Progenitor Cells (OPCs), have not been successfully developed so far. Here, we will review key information on the structure of the NVN, and we will summarize the evidence on the role of inflammation in the emergence and the progress of MS, with a focus on the active response of OPCs. We will also present recent experimental evidence on the role of less investigated cellular elements of the NVN, such as pericytes and platelets, in the regulation of OPCs. Finally, we will discuss current and future treatments for MS., This work was supported by the Research Council of Finland (Suomen Akatemia) - Academy Project 370013 to Francisco J. Rivera; the Sigrid Jusélius Foundation (Sigrid Juséliuksen Säätiö) to Francisco J. Rivera; the Finnish Multiple Sclerosis Foundation (Suomen MS-Säätiö) to Francisco J. Rivera; and the Chilean National Agency for Research and Development (Agencia Nacional de Investigación y Desarrollo, ANID) - FONDECYT Regular 1201706 to Francisco J. Rivera. In addition to this, this work was supported by the Spanish Ministerio de Ciencia e Investigación-MCIN and the Agencia Estatal de Investigación-AEI (grant PID2022-143110OB-I00 funded by MCIN/AEI/10.13039/501100011033/and by “ERDF A way of making Europe”, by the European Union to Fernando de Castro and PID2024-161979OB-I00 funded by MICIU/AEI/13.13039/501100011033 and EDRF/EU to Alerie G. de la Fuente), a contract #050601240019 “LeukoReMy” (financed by Asociación Europea contra la Leucodistrofia-ELA -Spain- and Fundación Hesperia -Spain-) to Fernando de Castro and a Ramón y Cajal Fellowship from the Ministerio de Ciencia Inovación y Universidades, Agencia Estatal de Investigación (RYC2023-045776-I, funded by MICIU/AEI/13.13039/501100011033 and FSE+) to Alerie G. de la Fuente. Also, by a research grant from the Hellenic Foundation for Research and Innovation (HFRI-FM17-3395) to Ilias Kazanis., Open access publishing facilitated by Helsingin yliopisto, as part of the Wiley - FinELib agreement., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

Sonic Hedgehog signaling in oligodendrogenesis, myelination, demyelinating diseases, and remyelination

  • Marchena-Fernández, Miguel
  • Sánchez-Camacho Blázquez, Cristina
  • Muñoz-Sáez, Emma
  • Macías-Castellano, Alba
  • Castro Soubriet, Fernando de
The Hedgehog (HH) family includes Indian (IHH), Desert (DHH), and Sonic Hedgehog (SHH). HH signaling plays a crucial role in myelination and oligodendrocyte lineage development. SHH regulates the specification, proliferation, and migration of oligodendrocyte precursor cells (OPCs), being essential for myelin production and remyelination. The balance of SHH/SMO signaling affects both oligodendrocyte differentiation and demyelinating disease progression. Understanding this pathway may open new therapeutic strategies for multiple sclerosis and leukodystrophies.